Navigating the Whirlwind Surrounding N-Nitrosamine Impurities in APIs and Drug Products
October 1, 2025
FDA Practice Group Leader David Rosen is speaking in SAAMnow’s Fall Workshop in the session “Navigating the Whirlwind Surrounding N-Nitrosamine Impurities in APIs and Drug Products” on October 1.
The workshop will focus on regulatory, scientific, and technical challenges surrounding the presence of N-nitrosamine impurities in active pharmaceutical ingredients (APIs) and drug products. Participants will explore cutting-edge methods, regulatory updates, and research developments regarding N-nitrosamines.
The workshop will address:
- U.S. Food and Drug Administration (FDA) perspective on N-Nitrosamine Impurities,
- International Generic and Biosimilar Medicines Association (IGBA) perspective on nitrosamine impurities, the worldwide challenges,
- ICH M7 risk assessment and control of N-nitrosamine impurities,
- Over-the counter (OTC) drug products and their challenges with N-nitrosamine impurities, and
- Prescription drug products and their challenges with N-Nitrosamine impurities.
People
Related Insights
January 2, 2026
Manufacturing Industry Advisor
Federal Court Denies Claim that Franchisor Is a Joint Employer with Franchisee
A federal court recently dismissed employment discrimination claims against a franchisor asserted by its franchisees’ employee after…
December 29, 2025
Tariff & International Trade Resource
Mexican January 2026 Tariff Tsunami: Maquilas Aren’t Immune
On January 1, 2026, Mexico will increase its general import tariff rate (known as the most favored nation (MFN) rate). The increase will be in the range of five to fifty percent, impacting 1,463 eight-digit tariff lines encompassing thousands of products originating in countries with which Mexico does not have a free trade agreement (FTA or the measure).
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.